Far from resolved: Stromal cell-based iTRAQ research of muscle-invasive bladder cancer regarding heterogeneity

Liu,Peng-Fei; Wang,Yong-Hua; Cao,Yan-Wei; Jiang,Hai-Ping; Yang,Xue-Cheng; Wang,Xin-Sheng; Niu,Hai-Tao

doi:10.3892/or.2014.3340

Far from resolved: Stromal cell-based iTRAQ research of muscle-invasive bladder cancer regarding heterogeneity

Authors:
- Peng-Fei Liu
- Yong-Hua Wang
- Yan-Wei Cao
- Hai-Ping Jiang
- Xue-Cheng Yang
- Xin-Sheng Wang
- Hai-Tao Niu
View Affiliations

Affiliations: Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao 266101, P.R. China, Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao 266101, P.R. China
Published online on: July 18, 2014 https://doi.org/10.3892/or.2014.3340
Pages: 1489-1496

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to globally characterize the cancer stroma expression profile of muscle-invasive bladder cancer in different metastatic risk groups and to discuss the decisive role of biological pathway change in cancer heterogeneity. Laser capture microdissection was employed to harvest purified muscle-invasive bladder cancer stromal cells derived from 30 clinical samples deriving from 3 different metastatic risk groups. Isobaric tags for relative and absolute quantitation (iTRAQ) and two-dimensional liquid chromatography tandem mass spectrometry (2D LC-MS/MS) were used to identify the differentially expressed proteins. Subsequently, the differentially expressed proteins were further analyzed by bioinformatics tools. After completing the above tasks, the proteins of interest were further compared with the published litterature. We identified 1,049 differentially expressed proteins by paired comparison (high risk vs. median, low risk and normal groups; median risk vs. low risk and normal groups, low risk vs. normal group; a total of 6 comparisons). A total of 510,549,548 proteins as significantly altered (ratio fold-change ≥1.5 or ≤0.667 between the metastatic potential risk group and the normal group) were presented in the low/median/high metastatic risk group, respectively. Pathway analysis revealed that the differentially expressed proteins were mainly located in the Kyoto Encyclopedia of Genes and Genomes pathways, including focal adhesion pathway, systemic lupus erythematosus pathway and ECM-receptor interaction pathway. In addition, several proteins such as EXOC4, MYH10 and MMP-9 may serve as candidate biomarkers of muscle-invasive bladder cancer. Our study confirmed that stromal cells, an important part of the cancer tissue, are pivotal for regulating the heterogeneity of cancer. Common changes in biological pathways determined the malignant phenotype of muscle-invasive bladder cancer, and biomarker discovery should take into account both neoplastic cells and their corresponding stromata.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer Statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
2	Pasin E, Josephson DY, Mitra AP, Cote RJ and Stein JP: Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol. 10:31–43. 2008.PubMed/NCBI
3	Knowles MA: Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis. 27:361–373. 2006. View Article : Google Scholar : PubMed/NCBI
4	Hasebe T: Tumor-stromal interactions in breast tumor progression - significance of histological heterogeneity of tumor-stromal fibroblasts. Expert Opin Ther Targets. 17:449–460. 2013. View Article : Google Scholar : PubMed/NCBI
5	van der Horst G, Bos L and van der Pluijm G: Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma. Mol Cancer Res. 10:995–1009. 2012.PubMed/NCBI
6	De Sousa E, Melo F, Vermeulen L, Fessler E and Medema JP: Cancer heterogeneity - a multifaceted view. EMBO Rep. 14:686–695. 2013.PubMed/NCBI
7	Niu HT, Shao SX, Zhang ZL, et al: Quantitative risk stratification and individual comprehensive therapy for invasive bladder cancers in China. Int Urol Nephrol. 41:571–577. 2009. View Article : Google Scholar : PubMed/NCBI
8	Tong W, Harris S, Cao X, et al: Development of public toxicogenomics software for microarray data management and analysis. Mutat Res. 549:241–253. 2004. View Article : Google Scholar : PubMed/NCBI
9	Memon AA, Chang JW, Oh BR and Yoo YJ: Identification of differentially expressed proteins during human urinary bladder cancer progression. Cancer Detect Prev. 29:249–255. 2005. View Article : Google Scholar : PubMed/NCBI
10	Guo C, Liu S, Wang J, Sun MZ and Greenaway FT: ACTB in cancer. Clin Chim Acta. 417:39–44. 2013. View Article : Google Scholar : PubMed/NCBI
11	Andersen CL, Jensen JL and Ørntoft TF: Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 64:5245–5250. 2004. View Article : Google Scholar
12	Saviozzi S, Cordero F, Lo Iacono M, Novello S, Scagliotti GV and Calogero RA: Selection of suitable reference genes for accurate normalization of gene expression profile studies in non-small cell lung cancer. BMC Cancer. 6:2002006. View Article : Google Scholar : PubMed/NCBI
13	Ma J, Cai W, Zhang Y, et al: Innate immune cell-derived microparticles facilitate hepatocarcinoma metastasis by transferring integrin α(M)β₂ to tumor cells. J Immunol. 191:3453–3461. 2013.PubMed/NCBI
14	Nishihira J, Ishibashi T, Fukushima T, Sun B, Sato Y and Todo S: Macrophage migration inhibitory factor (MIF): Its potential role in tumor growth and tumor-associated angiogenesis. Ann NY Acad Sci. 995:171–172. 2003. View Article : Google Scholar : PubMed/NCBI
15	Jung H, Seong HA and Ha H: Critical role of cysteine residue 81 of macrophage migration inhibitory factor (MIF) in MIF-induced inhibition of p53 activity. J Biol Chem. 283:20383–20396. 2008. View Article : Google Scholar : PubMed/NCBI
16	Oda S, Oda T, Nishi K, et al: Macrophage migration inhibitory factor activates hypoxia-inducible factor in a p53-dependent manner. PLoS One. 3:e22152008. View Article : Google Scholar : PubMed/NCBI
17	Kanoh Y, Ohtani H, Egawa S, Baba S and Akahoshi T: Changes of proteases and proteinase inhibitors in androgen-dependent advanced prostate cancer patients with alpha2-macroglobulin deficiency. Clin Lab. 58:217–225. 2012.
18	Misra UK, Payne S and Pizzo SV: Ligation of prostate cancer cell surface GRP78 activates a proproliferative and antiapoptotic feedback loop: a role for secreted rostate-specific antigen. J Biol Chem. 286:1248–1259. 2011. View Article : Google Scholar : PubMed/NCBI
19	Brunner A and Tzankov A: The role of structural extracellular matrix proteins in urothelial bladder cancer (review). Biomark Insights. 2:418–427. 2007.PubMed/NCBI
20	Ioachim E, Michael M, Stavropoulos NE, Kitsiou E, Salmas M and Malamou-Mitsi V: A clinicopathological study of the expression of extracellular matrix components in urothelial carcinoma. BJU Int. 95:655–659. 2005. View Article : Google Scholar : PubMed/NCBI
21	Henke CA, Roongta U, Mickelson DJ, Knutson JR and McCarthy JB: CD44-related chondroitin sulfate proteoglycan, a cell surface receptor implicated with tumor cell invasion, mediates endothelial cell migration on fibrinogen and invasion into a fibrin matrix. J Clin Invest. 97:2541–2552. 1996. View Article : Google Scholar
22	Yamamoto S, Tsuda H, Honda K, et al: ACTN4 gene amplification and actinin-4 protein overexpression drive tumour development and histological progression in a high-grade subset of ovarian clear-cell adenocarcinomas. Histopathology. 60:1073–1083. 2012. View Article : Google Scholar
23	Giubellino A, Burke TR Jr and Bottaro DP: Grb2 signaling in cell motility and cancer. Expert Opin Ther Targets. 12:1021–1033. 2008. View Article : Google Scholar : PubMed/NCBI
24	Seong J, Wang N and Wang Y: Mechanotransduction at focal adhesions: from physiology to cancer development. J Cell Mol Med. 17:597–604. 2013. View Article : Google Scholar : PubMed/NCBI
25	Yamamoto A, Kasamatsu A, Ishige S, et al: Exocyst complex component Sec8: a presumed component in the progression of human oral squamous-cell carcinoma by secretion of matrix metalloproteinases. J Cancer Res Clin Oncol. 139:533–542. 2013. View Article : Google Scholar : PubMed/NCBI
26	Johnson JL, Pillai S, Pernazza D, Sebti SM, Lawrence NJ and Chellappan SP: Regulation of matrix metalloproteinase genes by E2F transcription factors. Rb-Raf-1 interaction as a novel target for metastatic disease. Cancer Res. 72:516–526. 2012. View Article : Google Scholar : PubMed/NCBI
27	Ramón de Fata F, Ferruelo A, Andrés G, Gimbernat H, Sánchez-Chapado M and Angulo JC: The role of matrix metalloproteinase MMP-9 and TIMP-2 tissue inhibitor of metalloproteinasas as serum markers of bladder cancer. Actas Urol Esp. 37:480–488. 2013.PubMed/NCBI
28	Woolner S, O’Brien LL, Wiese C and Bement WM: Myosin-10 and actin filaments are essential for mitotic spindle function. J Cell Biol. 182:77–88. 2008. View Article : Google Scholar : PubMed/NCBI
29	Ju XD, Guo Y, Wang NN, et al: Both Myosin-10 isoforms are required for radial neuronal migration in the developing cerebral cortex. Cereb Cortex. 24:1259–1268. 2013.PubMed/NCBI